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Eﬃcacy of leukemia inhibitory factor as a therapeutic for permanent large
vessel stroke diﬀers among aged male and female rats
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does not improve survival or decrease tissue damage after stroke in aged rats.
• LIF
female rats show partial motor skill recovery after LIF treatment.
• Aged
receptor localizes to cellular membranes in ischemic tissue to promote survival.
• LIF
• Brains of aged rats have much lower LIF receptor levels compared to young rats.
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Preclinical studies using rodent models of stroke have had diﬃculty in translating their results to human patients. One possible factor behind this inability is the lack of studies utilizing aged rodents of both sexes.
Previously, this lab showed that leukemia inhibitory factor (LIF) promoted recovery after stroke through antioxidant enzyme upregulation. This study examined whether LIF promotes neuroprotection in aged rats of both
sexes. LIF did not reduce tissue damage in aged animals, but LIF-treated female rats showed partial motor skill
recovery. The LIF receptor (LIFR) showed membrane localization in young male and aged rats of both sexes after
stroke. Although LIF increased neuronal LIFR expression in vitro, it did not increase LIFR in the aged brain. Levels
of LIFR protein in brain tissue were signiﬁcantly downregulated between young males and aged males/females
at 72 h after stroke. These results demonstrated that low LIFR expression reduces the neuroprotective eﬃcacy of
LIF in aged rodents of both sexes. Furthermore, the ability of LIF to promote motor improvement is dependent
upon sex in aged rodents.

1. Introduction
Stroke is the ﬁfth leading cause of death among Americans and a
leading cause of major disability. One of the most damaging types of
ischemic stroke, an emergent large vessel occlusion (ELVO), occurs
when a thrombus impedes blood ﬂow in a major cerebral artery. ELVO
patients have a high mortality rate, and survivors are often left with
profound deﬁcits in motor and cognitive function (Malhotra et al.,
2017). Intravenous administration of tissue plasminogen activator

(tPA), the only FDA-approved drug for ischemic stroke, is often ineﬀective in ELVO patients (Broderick et al., 2013; Ciccone et al., 2013;
Kidwell et al., 2013), and others are unable to undergo endovascular
thrombectomy (EVT). The permanent intraluminal middle cerebral arterial occlusion (MCAO) model of stroke best represents ELVO without
tPA administration or EVT. This model provides the opportunity to
discover new treatments to decrease mortality and disability resulting
from ELVO.
Treating large vessel stroke in rats requires an agent that promotes

Abbreviations: EBST, elevated body swing test; EVT, endovascular thrombectomy; LIF (R), leukemia inhibitory factor (receptor); MCA (O), middle cerebral artery
(occlusion); SOD (3), superoxide dismutase (3); tPA, tissue plasminogen activator
⁎
Corresponding author at: 741 S. Limestone, Lexington, KY 40536, United States.
E-mail addresses: stephanie.davis@uky.edu (S.M. Davis), lisa.collier1@uky.edu (L.A. Collier), sarah.goodwin2@uky.edu (S. Goodwin),
douglas.lukins@uky.edu (D.E. Lukins), david.k.powell@uky.edu (D.K. Powell), keith.pennypacker@uky.edu (K.R. Pennypacker).
https://doi.org/10.1016/j.brainres.2018.11.017
Received 16 October 2018; Received in revised form 7 November 2018; Accepted 12 November 2018
Available online 13 November 2018
0006-8993/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/BY/4.0/).

Brain Research 1707 (2019) 62–73

S.M. Davis et al.

A

neuroprotection and reduces peripheral inﬂammation. Leukemia inhibitory factor (LIF), a cytokine in the IL-6 family, has shown eﬃcacy in
animal models for neurological diseases, such as multiple sclerosis and
amyotrophic lateral sclerosis. Previous groups demonstrated that LIF
reduces neurodegeneration through pro-survival PI3K/Akt signaling
and by promoting the development of anti-inﬂammatory leukocytes
(Azari et al., 2001; Butzkueven et al., 2002, 2006; Duluc et al., 2007;
Janssens et al., 2015; Slaets et al., 2008; Suzuki et al., 2005). This laboratory has shown that systemic LIF administration is eﬀective in reducing infarct volume and improving functional recovery after MCAO
(Rowe et al., 2014). This drug regimen entails an initial dose delivered
intravenously starting at 6 h after MCAO followed by additional doses
at 24 and 48 h with euthanization at 72 h. This regimen was initiated to
be clinically relevant and to encompass the neuroinﬂammatory-induced
neurodegeneration that occurs at 48 h in this model (Leonardo et al.,
2010).
LIF protects neurons and oligodendrocytes from an ischemic environment through the upregulation of antioxidant enzymes (Davis
et al., 2017; Rowe et al., 2014). LIF is also an anti-inﬂammatory cytokine that promotes the development of an anti-inﬂammatory phenotype
in macrophages and T helper cells (Duluc et al., 2007; Gao et al., 2009;
Janssens et al., 2015; Metcalfe et al., 2015). These combined actions
lead to improved histological and functional outcomes in this severe
stroke model.
Neuroprotective signaling begins with LIF binding to the LIF receptor (LIFR), a 190 kDa member of the type 1 cytokine receptor family
(Gadina et al., 2001). To confer downstream signaling, LIFR must be
localized to the plasma membrane and near other IL-6 cytokine receptor components. Besides LIF, this receptor transduces signals of two
other cellular protective proteins, cardiotropin-1 and ciliary neurotrophic factor. This receptor is unusual in that it resides in the nuclei of
neuronal cells until an injury occurs (Davis et al., 2017; Gardiner et al.,
2002; Zhao et al., 2014). While LIFR plays a crucial role in transducing
signals for these protective factors, the molecular and cellular roles of
this receptor are not entirely understood.
Until now, pre-clinical studies aimed at promoting post-stroke recovery have primarily utilized primarily young male rodents.
Unfortunately, results from these studies have not led to success in
clinical trials. We have reported favorable results with the administration of LIF as a neuroprotective agent in young male rats (Davis
et al., 2017; Konoeda et al., 2010; Rowe et al., 2014). In this study, we
utilized the same drug regimen and experimental design using aged
(18 mo) rats of both sexes. Our study shows that LIF treatment is less
eﬀective at promoting neuroprotection after MCAO in aged rats of both
sexes, which coincides with signiﬁcantly lower LIFR expression in the
brain compared to young rats.

B

Fig. 1. Kaplan-Meier curves show survival among (A) aged male rats and (B)
aged female rats (sham-operated, PBS-treated, and LIF treated up to 72 h after
MCAO. There was no signiﬁcant diﬀerence in survival between sexes or treatment groups. n = 9–17 animals per treatment group.

after MCAO (Fig. 2A). Likewise, there was no signiﬁcant diﬀerence in
the infarct volume between sexes (F1,25 = 0.1499; p = 0.7019) or
treatment groups (F1,25 = 0.1372; p = 0.7142) at 72 h post-MCAO
(Fig. 2B). However, there was a trend towards decreased edema volume
and infarct volume after LIF treatment among aged female rats.
2.3. Aged female rats show partial motor recovery after LIF treatment
Previously, this lab demonstrated that LIF administration after
permanent large vessel stroke promotes motor skill recovery (Rowe
et al., 2014). There was a trend towards improvement in LIF-treated
female rats compared to PBS-treated female rats according to the Circling test that approached signiﬁcance (χ2 = 2.524, df = 1, p = 0.056).
However, male rats did not show decreased circling after LIF treatment
(χ2 = 0.08184, df = 1, p = 0.3874; Fig. 3A). There was a signiﬁcant
two-way interaction between sex and drug treatment among the results
for the EBST (F1,48 = 6.529, p = 0.0138). Upon further analysis, there
was a signiﬁcant decrease in swing bias between male and female LIFtreated rats (t = 3.646, df = 24, p = 0.0006). Female LIF-treated rats
also showed a signiﬁcant decrease in step bias compared to PBS-treated
female rats (t = 2.548, df = 10, p = 0.0145; Fig. 3B). LIF-treated female rats also showed signiﬁcant improvement according to the Paw
Extension test compared to their PBS-treated counterparts (χ2 = 3.706,
df = 1, p = 0.0271), but male LIF-treated rats did not show improvement compared to PBS-treated rats (χ2 = 1.299, df = 1, p = 0.1272;
Fig. 3C). The results of the Step Bias Test showed no signiﬁcant improvement according to sex (F1,18 = 0.1409, p = 0.7118) or treatment
(F1,18 = 0.09829, p = 0.7575; Fig. 3D).

2. Results
2.1. Stroke-related mortality is not altered by sex or LIF treatment
The rates of mortality among aged male and female rats after
MCAO + PBS and MCAO + LIF treatment were compared using the
Mantel-Cox test. Mortality rates after sham surgeries are shown as a
negative control. There was no signiﬁcant diﬀerence in survival between sexes and treatment groups (χ2 = 0.3448, df = 3, p = 0.9514;
Fig. 1).
2.2. LIF treatment does not reduce tissue damage after MCAO
Before euthanizing animals, MRI scans were used to measure the
volume of edema (T2) and infarcted tissue (DTI) in the brains of PBS
and LIF-treated aged rats. Sham-operated animals of both sexes were
included as a negative control for tissue damage. There was no signiﬁcant diﬀerence in edema volume between sexes (F1,32 = 0.7368,
p = 0.3971) or treatment groups F1,32 = 0.4469, p = 0.5086) at 72 h

2.4. LIF does not upregulate SOD activity in aged rat brains after MCAO
LIF treatment decreases tissue damage after MCAO in young male
63
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Fig. 2. (A) MRI scans were used to assess edema (T2) and infarct volume (DTI) at 72 h after MCAO. Although there was not a signiﬁcant overall diﬀerence in (B)
edema or (C) infarct volume between PBS- or LIF-treated male and female rats, there was a trend towards decreased tissue damage after LIF treatment in aged female
rats. n = 9–17 animals per treatment group.

in the ipsilateral tissue of PBS and LIF-treated young male rats at 72 h
after MCAO (Fig. 5A). LIFR staining was also visualized in DAB-stained
tissue sections from LIF-treated young male rats. Although LIFR remained localized to cellular nuclei in the contralateral cortex, membrane localization of LIFR was observed in the ipsilateral cortex
(Fig. 5B).
Tissue sections from aged male and female rats were also stained
with LIFR (red) and MAP2 (green) antibodies to visualize LIFR in the
ipsilateral and contralateral cortices. Membrane localization of LIFR
was observed in cortical neurons in the ipsilateral tissue of both sexes
and treatment groups (Fig. 6A). DAB-stained tissue sections from aged
male and female animals revealed a similar staining pattern to that of
the young male rats. While LIFR was mainly localized to the neuronal
nuclei in the contralateral cortices of male and female rats in both
treatment groups, LIFR membrane localization was observed in the
ipsilateral cortices of both sexes and treatment groups (Fig. 6B).

rats by increasing SOD activity in the brain. SOD activity was measured
in the ipsilateral tissue from aged male and female rats to determine
whether LIF treatment promotes antioxidant activity in the aged brain.
Tissue from sham rats of both sexes is shown as a negative control.
There was no signiﬁcant change in SOD activity between sexes
(F1,12 = 0.5283 p = 0.4813) or treatment groups (F1,12 = 0.1919,
p = 0.6691; Fig. 4).

2.5. LIFR translocates to the cell membrane during stroke
This lab previously showed that LIFR is localized to the nuclei of
cortical neurons in vivo (Davis et al., 2017). However, LIFR has previously been shown to translocate from the nucleus to the membrane
during neuronal injury to promote neuroprotective signaling (Gardiner
et al., 2002). Representative tissue sections from young male rats were
labeled with antibodies against LIFR (red) and MAP2 (green to visualize
the localization of LIFR after MCAO. Punctate LIFR immunoreactivity
was observed in the cytosol and membrane regions of cortical neurons
64
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2.6. LIF treatment increases LIFR expression in vitro but not in the aged
brain

Sham
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Previously, this lab demonstrated that 200 ng/ml LIF prior to 24 h
OGD reduced cell death in cultured neurons and increased gene expression of SOD3 (Davis et al., 2017). Real-time PCR was used to assess
levels of LIFR mRNA in cortical neurons treated with this concentration
of LIF or PBS prior to 24 h OGD. LIF, but not PBS treatment increases in
vitro expression of the LIFR gene (U = 0; p = 0.0286; Fig. 7A). Western
blot was used to determine whether the upregulation of LIFR occurs
after in vivo LIF administration. LIFR levels were not signiﬁcantly altered by sex (F1,12 = 0.04023, p = 0.841) or treatment
(F1,12 = 0.009275, p = 0.9249) at 72 h after MCAO (Fig. 7B).
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Fig. 3. Four tests were used to determine motor skill function at 72 h after MCAO. (A) For the Circling test, there was a trend towards improvement in aged female
LIF-treated rats that approached signiﬁcance compared to PBS-treated females, but this trend was not observed in aged males. (B) A signiﬁcant two-way interaction
was observed between sex and drug treatment in the EBST results; LIF-treated rats performed signiﬁcantly better than PBS-treated females and LIF-treated males. (C)
LIF-treated females showed signiﬁcant improvement compared to PBS-treated females in the Paw Extension test, but male LIF-treated rats showed no improvement
compared to PBS-treated males. (D) Neither males nor females showed improvement according to the Step Test results.

2.7. Post-MCAO LIFR expression signiﬁcantly decreases with age

Fig. 4. SOD activity was measured in the ipsilateral brain tissue samples from
aged male and female rats. Neither drug treatment (PBS or LIF) had any signiﬁcant eﬀect on SOD enzyme activity at 72 h after MCAO.

LIF transport into the CNS during injury occurs due to LIFR being
expressed by cerebral endothelial cells (Pan et al., 2000, 2006, 2008).
Representative brain tissue sections from LIF-treated young male and
aged animals of both sexes were labeled with antibodies against von
Willebrand Factor (vWF; green), an endothelial cell marker, and LIFR
65
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Fig. 5. (A) Representative ipsilateral brain tissue sections from PBS and LIF-treated young rats were stained with antibodies against LIFR (red) and MAP2 (green).
DAPI (blue) was used to label cell nuclei. LIFR immunoreactivity was apparent in the cytosol and membrane regions of neurons at 72 h after MCAO. Arrows indicate
representative cells. Scale bar = 20 µm. (B) After LIF treatment, membrane localization of LIFR was apparent in the ipsilateral cortex, but nuclear localization of LIFR
was more prominent in the contralateral cortex. Arrows indicate representative cells. Scale bar = 50 μm.

3. Discussion

(red) to determine LIFR expression in the cerebral vascular endothelium. Several LIFR+ endothelial cells were identiﬁed in the brain
tissue from young male rats. However, there appears to be a notably
lower number of LIFR+ endothelial cells in the cerebral vasculature of
aged male and female rats that received LIF after MCAO (Fig. 8).
Western blotting was also used to determine whether LIFR levels in
the ischemic brain diﬀered signiﬁcantly between young male rats and
their aged counterparts of both sexes. Levels of LIFR in the contralateral
hemispheres of all age groups and sexes are shown as negative controls.
There was a signiﬁcant change in brain LIFR levels in the ipsilateral
tissue from young male, aged male, and aged female rats at 72 h after
MCAO (F2,10 = 32 p < 0.0001). Young male rats had signiﬁcantly
higher levels of LIFR compared to aged male rats (p = 0.0003) and
aged female rats (p = 0.0001). There was also a signiﬁcant diﬀerence in
LIFR levels between aged male and aged female rat brains
(p = 0.0091). A representative western blot showing expression of LIFR
in young and aged rat brains is shown in Fig. 9.

Previously, we have reported the protective eﬀects of LIF in young
male rats after MCAO. Here we ﬁnd that the same paradigm is not effective in aged male rats and has only a partially beneﬁcial eﬀect on
functional recovery in aged females. Reduced expression of LIFR may
be responsible for this discrepancy. While increased SOD3 expression
and SOD activity are observed after LIF treatment in young male rats,
this phenomenon is not found in aged male or female rats after MCAO
and LIF treatment (Davis et al., 2017). The reduced expression of LIFR
in the brain is possibly impairing the ability of LIF to induce antioxidant
enzymes to reduce oxidative injury in brain tissue.
LIF treatment has shown eﬃcacy in animal models of neurological
disorders, including stroke (Suzuki et al., 2005), amyotrophic lateral
sclerosis ALS (Azari et al., 2001, 2003; Konoeda et al., 2010) and
multiple sclerosis (MS) (Butzkueven et al., 2002, 2006). The application
of LIF also mitigates the macrophage/microglial response to injury that
contributes to the prolonged cell death in stroke (Hendriks et al., 2008).
66

Brain Research 1707 (2019) 62–73

S.M. Davis et al.

Fig. 6. (A) Representative ipsilateral brain
tissue sections from PBS- and LIF-treated aged
male and female rats were stained with antibodies against LIFR (red) and MAP2 (green) to
visualize LIFR localization after MCAO. Nuclei
were labeled with DAPI (blue). Stained contralateral tissue served as a negative control.
LIFR localization in neuronal nuclei and cytosolic/membrane regions was found in cortical
neurons from rats in all treatment groups.
Arrows indicate representative cells. (B) DABstained tissue sections also showed membrane
localization of LIFR in the ipsilateral tissue of
all treatment groups. Arrows indicate representative cells. Scale bar = 50 μm.

including our laboratory’s report examining cortical neurons in vitro
and in vivo (Couvreur et al., 2011; Davis et al., 2017; Gardiner et al.,
2002; Gouin et al., 1999; Zhao et al., 2014). Several groups previously
reported that CNTF and its receptor components, LIFR, gp130, and the
ciliary neurotrophic factor receptor (CNTFR), were able to cross the
nuclear envelope and resided primarily in the nucleus (Bajetto et al.,
1999; Couvreur et al., 2011). Nuclear localization has previously been
observed for cytokine receptors outside of IL-6 receptor family, such as
the interferon gamma receptor 1 (Larkin et al., 2000). In this study,
LIFR migrated from the perinuclear region and cytosol towards the
membrane after MCAO regardless of drug treatment. This movement of
LIFR towards the membrane was observed in young male, aged male,
and aged female rats that were administered LlF after MCAO (Figs. 5
and 6). These ﬁndings are consistent with a report published by Gardiner et al., which demonstrated that LIFR moved from the neuronal
nuclei to the plasma membrane during injury (Gardiner et al., 2002).
In addition to its role as a mediator of downstream pro-survival

Anzari et al. revealed LIF decreased the degradation of motor neurons
in the G93A SOD1 mouse model of familial ALS and reduced white
matter damage after spinal cord injury (Azari et al., 2001, 2003, 2006).
In an experimental MS model, administration of this agent directly affected white matter damage by inhibiting demyelinating injury (Azari
et al., 2006; Emery et al., 2006). Following induction of experimental
MS, oligodendrocytes upregulate LIFR in vivo, which appears to be an
endogenous mechanism of sensitizing white matter to the protective
eﬀects of LIF (Butzkueven et al., 2002, 2006; Hendriks et al., 2008;
Laterza et al., 2013). LIF treatment also has shown a great of promise in
treating MS (Metcalfe, 2011) and is being considered for clinical trials.
However, these previously published studies utilized young rodents of
both sexes. Furthermore, Suzuki et al. also reported the neuroprotective
signaling of LlF after stroke, but this study only used young male rats.
To our knowledge, these data are the ﬁrst to test the neuroprotective
eﬃcacy of LIF in aged male and female rodents.
The nuclear localization of LIFR has been reported in a few studies
67
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LIF in aged rats could be the basis of the lack of eﬃcacy. Further studies
are necessary to determine whether advanced age or sex diﬀerences
aﬀect the rate of transport of LIF across the blood-brain during injury.
Although the translocation of LIFR during stroke occurred in young
and aged rats of both sexes, these data show an age-dependent downregulation of LIFR expression in brain tissue. Downregulation of neurotrophic receptors, such as the brain-derived neurotrophic factor and
the nerve growth factor receptors, has previously been reported in the
aged rodent brain (Gómez-Pinilla et al., 1989; Silhol et al., 2005, 2007).
Treatment with LIF prior to 24 h OGD does signiﬁcantly increase expression of its receptor in neuronal cultures, but these neurons originate
from rat fetuses at day 18 of embryonic development. While both sexes
from aged rats failed to induce LIFR, the female rats did show functional improvement while the males did not. Moreover, LIF treatment
did not increase SOD activity and expression in aged rats as it did in the
young rats (Davis et al., 2017). The lower levels of LIFR could be due to
age-dependent changes in the epigenetic regulation of the LIFR gene
promoter. Previous reports have shown that LIFR transcription increases following acetylation of the promoter region (Johnson et al.,
2016; Zeng et al., 2016) and through downregulation of the transcription factor hypoxia-inducible factor 1-α, which downregulates
LIFR under hypoxic conditions (Jeong et al., 2007; Lee et al., 2010).
Methylation of the LIFR promoter region suppresses transcription of the
LIFR gene (Cho et al., 2011). Histone deacetylases, which are responsible for de-acetylating the LIFR promoter, have higher activity in
the brain of the aged rat (dos Santos Sant’Anna et al., 2013). In addition, aberrant patterns of DNA methylation are associated with the
aging process, which leads to dysregulated gene expression (Johnson
et al., 2012). Changes in epigenetic regulation that occur in advanced
age could explain the low expression of LIFR in the aged brain after
stroke. Furthermore, lower levels of LIFR are a possible explanation for
the poor neuroprotective eﬃcacy by LIF in aged rats compared to their
younger counterparts. Although direct neuroprotection was not observed in aged male or female rats after LIF treatment, our lab has
shown LIF treatment attenuates the post-stroke peripheral inﬂammatory response in aged female rats but not aged males (Davis
et al., 2018). This reduction in inﬂammation could explain why aged
females fare better after LIF treatment despite having lower overall
levels of LIFR in the CNS compared to aged males (Fig. 9).
However, more research is necessary to determine the sex-dependent eﬀects of LIF on the post-stroke immune response. After LIF
treatment, aged females have a better stroke outcome overall relative to
the males indicating a sex diﬀerence in response to this anti-inﬂammatory cytokine. Diﬀerential responses to treatment have been
observed in human patients. One such example is the use of uric acid as
a treatment for stroke that is eﬀective in women but not men
(Chamorro et al., 2014). This ﬁnding was initially unnoticed in the
clinical trial until results were broken out according to sex (Chamorro
et al., 2014; Romanos et al., 2007). Furthermore, results from preclinical studies in aged rodents suggest that targeting the post-stroke
inﬂammatory response is eﬀective in aged female rodents (Chauhan
et al., 2018).
Preclinical stroke studies have been less than successful at translating successful animal studies into new therapeutics. One problem has
been the use of young male rodents in these studies. The vast majority
of stroke patients are middle-aged to elderly individuals of both sexes,
and the risk for stroke doubles every 10 years after the age of 55 (Chong
and Sacco, 2005; Ovbiagele and Nguyen-Huynh, 2011). Not only is
there an age mismatch between the typical stroke patient and animal
models, but also a sex mismatch because most young rodents used in
stroke studies are male. The use of young male rats is due to the confounding eﬀect of estrogen in preclinical stroke studies (Hawk et al.,
1998; Seifert and Oﬀner, 2018; Simpkins et al., 1997; Zhang et al.,
2010). According to several studies by Alkayed et al., young female rats
(3–4 mo.) showed signiﬁcantly smaller infarcts and less several functional damage compared to their age-matched male counterparts.

B
LIFR

Male LIF Con
Male PBS Ips
Male PBS Con

Female PBS Con
Male LIF Ips

Female LIF Ips
Female LIF Con
Female PBS Ips

ȕ-Actin

Fig. 7. (A) Primary neurons were treated with PBS or LIF and subjected to 24 h
OGD. LIFR mRNA was signiﬁcantly elevated in neurons treated with LIF compared to those treated with PBS (*p < 0.05). n = 3 wells per group. (B)
However, LIFR expression in the ipsilateral tissue of aged rats of both sexes was
not altered by LIF treatment at 72 h after MCAO.

signaling, LIFR acts as a transporter of LIF across endothelial cells.
According to Pan et al., LIFR expressed by cerebral endothelial cells is
responsible for mediating transcellular LIF transport across the bloodbrain barrier. Furthermore, the rate of LIF transport into the central
nervous system is increased by brain injury and pro-inﬂammatory cytokines such as tumor necrosis factor-α (Pan et al., 2000, 2006, 2008).
This mechanism allows LIF to traverse the blood-brain barrier to enter
the brain parenchyma to elicit its neuroprotective and anti-inﬂammatory eﬀects. According to these data, LIFR expression is localized in some brain endothelial cells of aged rats, but not all endothelial
cells in the cerebral microvasculature (Fig. 8). Loss of the transport of
68
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Young Male LIF

Aged Male LIF

Aged Female LIF

20x

63x

Fig. 8. Brain tissue sections from young male and aged (male and female) LIF-treated rats were stained with antibodies against LIFR (red) and vWF (green) to
visualize LIFR localization to cerebral endothelial cells. DAPI (blue) was used to label nuclei. LIFR-positive endothelial cells were visualized in after LIF-treated in the
brains of young male rats. LIFR immunoreactivity was less prominent in the brains of LIF-treated aged male and female rats compared to young male rats. Scale
bar = 50 μm.

demonstrate the importance of testing and optimizing potential stroke
therapies in animal models that best represent the age and sex of stroke
patients.

Meanwhile, ovariectomized females did not show signiﬁcantly smaller
infarcts compared to male rats (Alkayed et al., 1998). In a subsequent
report, aged female rats (16 mo.) did not show a signiﬁcant diﬀerence
in infarct size compared to age-matched males. In human patients, the
severity of stroke-induced brain damage is often signiﬁcantly higher in
female patients compared to male patients (Appelros et al., 2009).
These data show the necessity of performing preclinical studies in animals that best resemble their human counterparts; namely, aged male
and female rodents.
Reduced LIFR expression decreases responsiveness to exogenous LIF
and hinders the neuroprotective signaling from endogenous cytokines
that use LIFR, such as ciliary neurotrophic factor and cardiotrophin-1.
Further studies are needed to determine whether LIF promotes antiinﬂammatory signaling in an age- and sex-dependent matter. The eﬃcacy of LIF could potentially be improved through combination therapy
with drugs that increase expression of LIFR. HDAC inhibitors have been
shown to be neuroprotective after MCAO (Baltan et al., 2011; Kim et al.,
2007). In addition, histone deacetylase inhibitors promote LIFR upregulation by increasing acetylation of its gene promoter (Johnson et al.,
2016; Wirths et al., 2002; Zeng et al., 2016).

5. Methods and materials
5.1. Animal care
Retired breeding pairs of Sprague Dawley rats (9–10 mo.) were
purchased from Envigo (Indianapolis, IN) and housed until between the
age of 18–19 mo. Animals were housed in a climate-controlled room
with access to food and water ad libitum and kept on a 12 h light/dark
cycle (07:00–19:00 h). All animals were randomly assigned to treatment groups. All procedures were approved according to the University
of Kentucky Institutional Animal Care and Use Committee.

5.2. Middle cerebral artery occlusion (MCAO)
To induce permanent large vessel stroke, the intraluminal middle
cerebral artery occlusion (MCAO) method was performed as previously
described (Ajmo et al., 2006). Brieﬂy, animals were anesthetized using
5% isoﬂurane in 100% oxygen (1 L/min). Anesthesia was maintained at
3% isoﬂurane for the duration of the surgical procedure. An incision
was made on the neck to expose the common carotid artery, and the
external carotid was ligated and cut. A 40 mm monoﬁlament was fed
through the internal carotid artery and advanced to the origin of the
middle cerebral artery (MCA). Laser Doppler measurement was used to
conﬁrm the reduction in blood ﬂow. Animals with ≤60% reduction in
cerebral blood ﬂow were excluded from the study. For the sham procedure, the common carotid artery was exposed without occluding the
MCA.

4. Conclusion
From this study, we show that aged rats are less responsive to LIF
treatment after experimental stroke with females showing a trend towards decreased tissue damage and partial motor skill recovery and
males showing no response to LIF treatment. The decline of the expression of LIFR would be responsible for the reduced neuroprotective
signaling and transport into the brain. Furthermore, LIF does not promote protection against oxidative stress by increasing SOD activity in
aged animals as it does in young, male rodents (Davis et al., 2017). The
lack of responsiveness to exogenous LIF treatment may be explained by
the signiﬁcant downregulation of LIFR in the aged brain. These data
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balanced on one forepaw then drawn across the table. This process was
repeated using the opposite forelimb, and the number of paw plants was
recorded for each side. Measurements were recorded at baseline
(3–4 days before surgery) and 72 h after MCAO. Results of the EBST and
Step Tests were expressed as a change from baseline.

C

5.5. Magnetic resonance Imaging (MRI)

LIFR

MRI images were acquired using a 7 T Bruker Clinscan horizontal
bore system (7.0 T, 30 cm, 300 Hz) equipped with a triple-axis gradient
system (630 mT/m and 6300 T/m/s) with a closed cycle (Billerica, MA).
Coronal Diﬀusion Tensor Imaging (DTI) images will were acquired with
a fat saturated, double refocused echo planar sequence:
0.297 × 0.297 × 0.7 mm3, TR/TE 2200/34, 128 × 128 matrix, 3 av, 15
slices, four b = 0 volumes, 256 directions with b = 800, in 28:23 min.
Coronal T2-weighted images were acquired with a fat saturated, turbo
spin echo sequence: 0.125 × 0.125 × 0.4 mm3 resolution, TR/TE
6000/27, 192 × 192 matrix, 44 slices, is 9:03.
Male animals were anesthetized with an average of 2.25% isoﬂurane in oxygen, while female animals will be anesthetized with an
average of 1.75% isoﬂurane in oxygen using MRI-compatible CWE Inc.
equipment (Ardmore, PA). Animals were restrained on a Bruker scanning bed using a tooth bar and tape. Body temperature, heart rate, and
respiratory rates were continuously monitored throughout the MRI
scans (SA Instruments, Inc., Stony Brook, NY). Animals were maintained at 37° with a water heating system built into the scanning bed.
Infarct volume and edema volumes were measured using DTI and
T2-weighted MR images. Volumes were counted and normalized to the
number of images counted to provide a per section count. The volume
of brain parenchyma demonstrating restricted diﬀusion (infarct volume) visibly aﬀected by cerebral edema (edema volume) was calculated by manual segmentation using ITK-SNAP software as previously
described (Yushkevich et al., 2006). The volume of brain parenchyma
visibly aﬀected by cerebral edema (edema volume) will be calculated
similarly. Quantiﬁcation of infarct and edema volumes was performed
by a single individual who was blinded to the sex and treatment group
of each animal.

ȕ-Actin

Fig. 9. LIFR protein levels were measured in the ipsilateral brain tissue from the
young male, aged male, and aged female rats after MCAO. LIFR levels were
signiﬁcantly decreased in aged male (*p < 0.05) and aged female (*p < 0.05)
compared to young male rats. There was also a signiﬁcant decrease in LIFR
levels between aged male and aged female rats after MCAO. n = 4–6 animals
per treatment group.

5.6. Collection of tissue
5.3. Drug administration
Animals were euthanized at 72 h post-MCAO via intraperitoneal
injection of ketamine/xylazine solution (75 mg/kg and 7.5 mg/kg)
(Seifert et al., 2012). Animals underwent trans-cardial perfusion with
normal saline followed by 4% paraformaldehyde in phosphate buﬀer.
Fixed brains were cryopreserved in 20% followed by 30% sucrose solutions and cut into 30 µm sections using a cryostat. Animals used for
biochemical analysis were only perfused with normal saline before
obtaining tissue. Fresh tissue was snap frozen and stored at −80 °C
until further processing. The brains were separated into the right (ipsilateral) and left (contralateral) hemispheres, snap-frozen, and stored
at −80 °C. Brain tissue used in these experiments was located in the
region between +1.7 to −3.3 mm from bregma.

To control for post-surgical pain, all rats were treated prophylactically with carprofen (5 mg/kg s.c.) with two additional doses of carprofen at 24 and 48 h post-MCAO. Atropine (0.04 mg/kg s.c.) was administered to reduce secretions in the upper and lower respiratory tract
and improve breathing during surgery. Animals were randomly assigned to receive recombinant human LIF (125 μg/kg i.v.; ProSpec, Ness
Ziona, Israel) or PBS (pH 7.4) treatment at 6, 24, and 48 h post-MCAO
as previously described (Davis et al., 2017). Blinded personnel administered all drugs to animals.

5.4. Assessment of motor function
5.7. Whole cell tissue homogenization

Functional sensorimotor deﬁcits were measured as previously published using a battery of four tests immediately before euthanization
(Rowe et al., 2014). The following tests were used: Circling, Elevated
Body Swing Test (EBST), Paw Extension, and Step Bias tests. For the
Circling test, animals were placed in an open ﬁeld, and the presence or
absence of circling behavior was recorded. For the EBST, animals were
suspended by the tail, and the number of lateral “swings” toward the
left or right side was recorded. For the Paw Extension test, animals were
suspended by the tail, and the ability to extend the forelimb on the
aﬀected side was recorded. For the Step Bias test, each animal was

To obtain whole cell extracts, ipsilateral and contralateral brain
tissue was homogenized in whole cell lysis buﬀer containing the following: 50 mM Tris pH 8, 150 mM NaCl, 0.1% SDS, 1% Igepal CA-630,
1 mM PMSF, and a Complete Mini protease inhibitor cocktail (Roche
Diagnostics, Indianapolis, IN). Brieﬂy, tissue was disrupted using an
electric homogenizer and allowed to incubate on ice for 10 min. Tissue
was vortexed and pipetted to break up nuclei. Tissue was snap-frozen
and stored at −80 °C.
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5.8. Superoxide dismutase inhibition assay

5.12. Real-time PCR

The activity of superoxide dismutase (SOD) enzymes in brain tissue
was measured using a colorimetric assay kit purchased from Kamiya
Biochemical (Tukwila, WA) (Davis et al., 2017). Brieﬂy, SOD activity
was measured in diluted brain tissue samples by measuring absorbance
at 450 nm using a microplate spectrophotometer (Biotek, Winnoski,
VT). A standard curve and the IC50 was calculated using the % inhibition at each dilution. The IC50 was used to calculate SOD activity (U/mg
protein).

5.12.1. RNA isolation and cDNA synthesis
RNA isolation and was performed as previously described (Rowe
et al., 2010). Total RNA was extracted from cells using an RNeasy Mini
Kit (Qiagen, Germantown, MD). Total RNA was reverse-transcribed
using an AﬃnityScript cDNA Synthesis Kit (Agilent Technologies, Santa
Clara, CA) and cDNA was quantiﬁed using a Nanodrop Lite Spectrophotometer (Thermo-Fisher Scientiﬁc, Waltham, MA).
5.12.2. PCR reaction
Real-time PCR was performed using PowerUp™ SYBR® Green Master
Mix (Applied Biosystems, Foster City, CA) on a StepOnePlus Real-Time
PCR System (Applied Biosystems). LIFR mRNA was ampliﬁed using
primers purchased from Qiagen and normalized to levels of 18 s rRNA
(Qiagen). The following protocol was used:
Hold at 50 °C for 2 min, hold at 95 °C for 2 min, and 40 cycles of
95 °C for 15 s followed by 60 °C for 1 min. Melt temp curve analysis was
performed after all cycles were completed using the following protocol:
95 °C for 15 s at a ramp rate of 1.6 °C/s, 60 °C for 1 min at a rate of
1.6 °C/second, and 95 °C for 15 s at a ramp rate of 0.15 °C/s. Relative
expression of LIFR was calculated using the ΔΔCt method as previously
described (Davis et al., 2017).

5.9. Western blot analysis
Western blotting was used for semi-quantitative measurement of
protein expression using a previously described procedure (Davis et al.,
2017). Brieﬂy, whole cell lysates from ipsilateral brain tissue were run
on 10% SDS-PAGE gels and transferred to nitrocellulose membranes.
Contralateral tissue was included alongside ipsilateral tissue to serve as
an internal negative control for the ischemic injury. Membranes were
blocked with 5% nonfat milk in TBS and probed with the following
antibodies: Rabbit anti-LIFR (C-19) (1:100; Santa Cruz Biotechnology,
Dallas, TX, US). Membranes were incubated in IRDye 800CW goat antirabbit antibodies (1:20,000; Li-Cor) for detection of protein bands.
Membranes were visualized using the Odyssey CLx Imaging System (LiCor). To normalize for loading, membranes containing whole cell extracts were re-probed with mouse anti-β-actin (1:5000; Novus Biologicals) and IRDye 680RD goat anti-mouse antibodies (1:20,000; Li-Cor).

5.13. Data analysis
Data were analyzed using GraphPad Prism 5.0 Software (La Jolla,
CA). Data from the Paw Extension and Circling tests were analyzed
using a Chi-Square Analysis. All other data were analyzed using an
ANOVA (one or two-way) followed by Fisher's LSD post hoc test
Student’s t-test was used to analyze data containing two treatment
groups. The Welch correction used in the case of signiﬁcant diﬀerence
in variances, the Mann-Whitney U Test were used to analyze nonnormal data. Statistical signiﬁcance was denoted by a p-value ≥ 0.05.
All reported p-values are one-tailed. The data in all ﬁgures are presented as the mean ± standard error of the mean.

5.10. Immunohistochemical staining
5.10.1. 3,3′-Diaminobenzidine staining
3,3′-diaminobenzidine staining was performed as previously described (Hall et al., 2009) using rabbit anti-LIFR (1:200; Santa Cruz
Biotechnology) and goat anti-rabbit biotinylated secondary antibodies
(1:300; Vector Laboratories, Burlingame, CA). Images were acquired
using a Zeiss AxioSkop 2 Microscope (Carl Zeiss, Oberkochen, Germany) or a Ti Inverted Microscope (Nikon, Tokyo, Japan).
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5.10.2. Fluorescent staining
Brain tissue sections were labeled as previously described (Hall
et al., 2009) using the following antibodies: rabbit anti-LIFR (1:200;
Santa Cruz Biotechnology), mouse anti-microtubule-associated protein
2 (MAP2) (1:200; EMD Millipore, Burlington, MA). Secondary detection
was achieved using goat anti-mouse AlexaFluor 488 (1:500; Life
Technologies) and goat anti-rabbit AlexaFluor 594 (1:500; Life Technologies). Sheep anti-von Willebrand Factor (vWF)-FITC (1:50; Abcam,
Cambridge, UK) was used to label cerebral blood vessels. Images were
acquired using a Ti Inverted Microscope.
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